New film will address industry challenges and support efficient production of biopharmaceuticals
CHALFONT ST. GILES, UK and CHARLOTTE, NC – 17 August 2016 – GE Healthcare’s Life Sciences business, a global provider of technologies and expertise to the biopharmaceutical and life sciences industries and Sealed Air Corporation, a global manufacturer of primary films for pharmaceutical solutions, today announced the expansion of a strategic alliance designed to further the development and innovation in the biopharmaceuticals industry.
The agreement marks the next stage of a long-term collaboration between GE and Sealed Air, following a successful research and development agreement which created a new film suitable for use across GE’s full single-use portfolio, supporting exceptional cell growth, application robustness, and enhancing security of supply.
Morgan Norris, GM of Upstream Products at GE Healthcare’s Life Sciences business, commented, “GE and Sealed Air share a vision of the importance of robust, high quality films in the efficient manufacture of life saving medicines such as monoclonal antibodies, vaccines and next generation biotherapeutics. Through this partnership we are confident that we will deliver the next level of purposefully constructed and manufactured films for bioprocessing applications, enabling improved performance, supply chain control, and material/supplier transparency that the market demands of single-use suppliers.”
Gareth Crain, Vice President and General Manager of Sealed Air’s Medical Applications division added, “The combination of GE’s industry knowledge and breadth of product portfolio, with our experience, established proven compliance and quality systems in the pharmaceutical market space, will enable us to deliver film solutions uniquely suited to the needs of single-use technology users in biomanufacturing. This agreement provides a great platform for us to leverage our expertise in polymers, pharmaceutical regulatory and in-market requirements. We have been present in the parenteral market for many years where our Nexcel™ M312™ film is considered to be best in class for IV solutions.”
About Sealed Air
Sealed Air Corporation creates a world that feels, tastes and works better. In 2015, the Company generated revenue of approximately $7.0 billion by helping our customers achieve their sustainability goals in the face of today’s biggest social and environmental challenges. Our portfolio of widely recognized brands, including Cryovac® brand food packaging solutions, Bubble Wrap® brand cushioning and Diversey® cleaning and hygiene solutions, enables a safer and less wasteful food supply chain, protects valuable goods shipped around the world, and improves health through clean environments. Sealed Air has approximately 23,000 employees who serve customers in 169 countries. To learn more, visit www.sealedair.com.
About Sealed Air Medical Applications
Sealed Air’s Medical Applications business is a leading global manufacturer of materials designed for the healthcare industry, including films for pharmaceutical solutions and barrier films for stoma and ostomy pouches marketed and sold under the NEXCEL® brand.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About GE Healthcare Life Sciences
GE Healthcare's $4B Life Sciences business is on a mission to accelerate an age of molecular and precision medicine by providing expertise, tools and solutions for a wide range of applications, including basic research of cells and proteins, drug discovery, cell therapy and regenerative medicine, as well as tools and technology to support large-scale manufacturing of biopharmaceuticals, vaccines and biologics such as insulin. It also supplies leading contrast, PET and nuclear medicine agents for diagnostic imaging to help doctors make more informed diagnoses for better patient outcomes. The company's mission is to help enable a new era of molecular and precision medicine by providing customers with the tools, insight and knowledge to guide them ever more quickly from better biological understanding to better clinical therapies.
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 concerning our business, consolidated financial condition and results of operations. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as “anticipates,” “believes,” “plan,” “assumes,” “could,” “should,” “estimates,” “expects,” “intends,” “potential,” “seek,” “predict,” “may,” “will” and similar references to future periods. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, expectations regarding the results of restructuring and other programs, anticipated levels of capital expenditures and expectations of the effect on our financial condition of claims, litigation, environmental costs, contingent liabilities and governmental and regulatory investigations and proceedings. The following are important factors that we believe could cause actual results to differ materially from those in our forward-looking statements: the tax benefits associated with the Settlement agreement (as defined in our 2015 Annual Report on Form 10-K), global economic and political conditions, changes in our credit ratings, changes in raw material pricing and availability, changes in energy costs, competitive conditions, success of our restructuring activities, currency translation and devaluation effects, the success of our financial growth, profitability, cash generation and manufacturing strategies and our cost reduction and productivity efforts, the effects of animal and food-related health issues, pandemics, consumer preferences, environmental matters, regulatory actions and legal matters, and the other information referenced in the “Risk Factors” section appearing in our most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Issued for and on behalf of GE Healthcare by Instinctif Partners.
For more information please contact: GE-Bioprocess@Instinctif.com